Showing 2991-3000 of 5621 results for "".
- Market Scope: Safer and More Effective Glaucoma Surgical Options Expected to Double Global Revenue by 2027https://modernod.com/news/market-scope-safer-and-more-effective-glaucoma-surgical-options-expected-to-double-global-revenue-by-2027/2481223/Nearly 48 million individuals are diagnosed with glaucoma globally, but just over a million, or 2.2 percent, will have surgery in 2022. However, safer and more effective surgical devices over the next 5 years will increase the percentage of glaucoma patients treated surgically to a projected 3.5
- Vyluma Announces Positive Results From Phase 3 CHAMP Study of NVK002 for Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-announces-positive-results-from-phase-3-champ-study-of-nvk002-for-treatment-of-myopia-progression-in-children/2481205/Vyluma announced topline results from its phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. Analysis of this multicenter, international study, performed after 3 years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment fo
- EyeMed Vision Care Names Matt MacDonald Presidenthttps://modernod.com/news/eyemed-vision-care-names-matt-macdonald-president/2481204/EyeMed has appointed Matt MacDonald to the role of President. Mr. MacDonald succeeds Lukas Ruecker who has decided to step down after 9 years for personal reasons. Mr. MacDonald has been with EyeMed since 2013, and most recently served as Chief Operations Officer. Prior to that, he
- Alcon to Celebrate 75 Years and Showcase Contact Lens Innovations at #Academy22https://modernod.com/news/alcon-to-celebrate-75-years-and-showcase-contact-lens-innovations-at-academy22/2481197/Alcon will feature a host of innovations across its portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 7
- Study: Digital Home Monitoring Shows Unique Predictive Value in Disease Progression for AMD Patientshttps://modernod.com/news/study-digital-home-monitoring-shows-unique-predictive-value-in-disease-progression-for-amd-patients/2481190/Notal Vision reported the publication of the second report of the "Analysis of Long-term visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT)" study results in Ophthalmology Retina. The 10-year retrospective study details the importance of digital remote monitor
- UCI Team Demonstrates the Adult Brain has the Potential to Partially Recover from Inherited Blindnesshttps://modernod.com/news/uci-team-demonstrates-the-adult-brain-has-the-potential-to-partially-recover-from-inherited-blindness/2481173/A discovery about how some visually impaired adults could start to see offers a new vision of the brain’s possibilities. The finding that the adult brain has the potential to partially recover from inherited blindness comes from a
- Moria Expands its Footprint into Eye Surgery by Acquiring Alchimia SRLhttps://modernod.com/news/moria-expands-its-footprint-into-eye-surgery-by-acquiring-alchimia-srl/2481161/France-based Moria has announced the acquisition of Italian-based company Alchimia SRL, a manufacturer of devices for ophthalmic surgery and human tissue banking. Financial terms of the deal were not disclosed. Founded in 1993, Alchimia has 30 years of expertis
- Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Greater Sensitivity than Dilated Examshttps://modernod.com/news/study-finds-eyenuk-artificial-intelligence-detects-diabetic-retinopathy-with-greater-sensitivity-than-dilated-exams/2481158/Eyenuk announced the publication of EyeArt validation results in Ophthalmology Science, a peer-reviewed journal of the American Academy of Ophthalmology. The study, titled “Artifici
- Clearside: Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platformhttps://modernod.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/Clearside Biomedical announced that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons. “These data presenta
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul